FibroBiologics Files Definitive Proxy Statement

TL;DR

FibroBiologics filed its proxy statement, shareholders vote soon.

AI Summary

FibroBiologics, Inc. filed a definitive proxy statement (DEF 14A) on July 8, 2024. The filing pertains to the company's annual meeting and related matters. The company is incorporated in Delaware and its fiscal year ends on December 31st. The filing fee was not required.

Why It Matters

This filing provides shareholders with essential information regarding the company's governance and upcoming decisions, allowing them to exercise their voting rights.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.

Key Players & Entities

• FibroBiologics, Inc. (company) — Registrant
• 0001493152-24-026435 (filing_id) — Accession Number
• 20240708 (date) — Filing Date
• 001-41934 (filing_id) — SEC File Number
• 77598 (zip_code) — Business Address Zip Code

FAQ

Key Financial Figures

• $0.00001 — our Series C Preferred Stock, par value $0.00001 per share, or the Series C Preferred St

Filing Documents

• formdef14a.htm (DEF 14A) — 598KB
• formdef14a_001.jpg (GRAPHIC) — 46KB
• formdef14a_002.jpg (GRAPHIC) — 98KB
• proxy_001.jpg (GRAPHIC) — 318KB
• proxy_002.jpg (GRAPHIC) — 271KB
• 0001493152-24-026435.txt ( ) — 1609KB

Executive Compensation

Executive Compensation 23 Summary Compensation Table 23 Other Elements of Compensation 25 Employment Agreements with our Executive Officers 26 Equity Compensation Plans 28 Outstanding Equity Awards at December 31, 2023 28 Director Compensation 28

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 30 EQUITY COMPENSATION PLAN INFORMATION 33 RELATED PERSON TRANSACTIONS 34 Certain Relationships and Related Transactions 34 Indemnification Agreements 35 OTHER MATTERS 36 Stockholder Proposals for 2025 Annual Meeting 36 Householding of Proxy Materials 36 Availability of Additional Information 36 Appendix A – Capital Decrease Amendment A-1 Appendix B – Clarifying Amendment B-1 FIBROBIOLOGICS, INC. 455 E. Medical Center Blvd., Suite 300 Houston, Texas 77598 281-671-5150 PROXY FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the Internet? Pursuant to rules adopted by the Securities and Exchange Commission, or the SEC, we have elected to provide access to our proxy materials over the Internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials, or the Notice, because the Board of Directors, or the Board, of FibroBiologics, Inc., or FibroBiologics, we, us or our, is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, or the Annual Meeting, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the Internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about July 8, 2024 to all stockholders of record entitled to vote at the Annual Meeting. Will I receive any other proxy materials by mail? We may send you a proxy card, along with a second Notice, on or after July 18, 2024. How do I attend the Annual Meeting? Stockholders as of the record date and/or their authorized represent

View Full Filing

View this DEF 14A filing on SEC EDGAR